ArticleOncogene2016
The homeoprotein DLX3 and tumor suppressor p53 co-regulate cell cycle progression and squamous tumor growth.
Article in Oncogene, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- CD271 orchestrates skin structure, differentiation, and inflammation via PI3K/Akt and PKCα/ERK pathways.Cell death & disease · 2025Article
- Metabolic reprogramming and prognostic modeling in pancreatic cancer: insights from WGCNA.Frontiers in genetics · 2025Article
- Identification and validation of DLX4 as a prognostic and diagnostic biomarker for clear cell renal cell carcinoma.Oncology letters · 2023Article
- Loss of DLX3 tumor suppressive function promotes progression of SCC through EGFR-ERBB2 pathway.Oncogene · 2021Article
- Article
- Identification of prognostic gene biomarkers for metastatic skin cancer using data mining.Biomedical reports · 2020Article
- Molecular Approach to Cutaneous Squamous Cell Carcinoma: From Pathways to Therapy.International journal of molecular sciences · 2020Article
- Do DLX3 and CD271 Protect Human Keratinocytes from Squamous Tumor Development?International journal of molecular sciences · 2019Article
- Transcript profiling in the testes and prostates of postnatal day 30 Sprague-Dawley rats exposed prenatally and lactationally to 2-hydroxy-4-methoxybenzophenone.Reproductive toxicology (Elmsford, N.Y.) · 2018Article
- Manic Fringe deficiency imposes Jagged1 addiction to intestinal tumor cells.Nature communications · 2018Article
- A data mining paradigm for identifying key factors in biological processes using gene expression data.Scientific reports · 2018Article
- Role of FGFR2b expression and signaling in keratinocyte differentiation: sequential involvement of PKCδ and PKCα.Cell death & disease · 2018Article
- DLX3-Dependent STAT3 Signaling in Keratinocytes Regulates Skin Immune Homeostasis.The Journal of investigative dermatology · 2018Article
- Homeobox transcription factor DLX4 is not necessary for skin development and homeostasis.Experimental dermatology · 2018Article
- DLX3 interacts with GCM1 and inhibits its transactivation-stimulating activity in a homeodomain-dependent manner in human trophoblast-derived cells.Scientific reports · 2017Article
- A novel DLX3-PKC integrated signaling network drives keratinocyte differentiation.Cell death and differentiation · 2017Article
- Senescence: novel insight into DLX3 mutations leading to enhanced bone formation in Tricho-Dento-Osseous syndrome.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
Epidermal homeostasis depends on the coordinated control of keratinocyte cell cycle. Differentiation and the alteration of this balance can result in neoplastic development. Here we report on a novel DLX3-dependent network that constrains epidermal hyperplasia and squamous tumorigenesis. By integrating genetic and transcriptomic approaches, we demonstrate that DLX3 operates through a p53-regulated network. DLX3 and p53 physically interact on the p21 promoter to enhance p21 expression. Elevating DLX3 in keratinocytes produces a G1-S blockade associated with p53 signature transcriptional profiles. In contrast, DLX3 loss promotes a mitogenic phenotype associated with constitutive activation of ERK. DLX3 expression is lost in human skin cancers and is extinguished during progression of experimentally induced mouse squamous cell carcinoma (SCC). Reinstatement of DLX3 function is sufficient to attenuate the migration of SCC cells, leading to decreased wound closure. Our data establish the DLX3-p53 interplay as a major regulatory axis in epidermal differentiation and suggest that DLX3 is a modulator of skin carcinogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.